Attention Deficit Hyperactivity Disorder: An Update

Advances in Therapy

Volumn 20, Issue 6, 2003, Pages 305-318

  Leung, Alexander K C ^a,b   Lemay, Jean François ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

Attention deficit; Daily dose; Hyperactivity; Stimulants

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMPHETAMINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; PEMOLINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANAMNESIS; ANXIETY DISORDER; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CHILD; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABUSE; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSPHORIA; EDUCATION; EUPHORIA; GROWTH RETARDATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERACTIVITY; HYPERTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LONG TERM CARE; MEDICAL TECHNOLOGY; MOOD DISORDER; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREVALENCE; PSYCHOSOCIAL WITHDRAWAL; REINFORCEMENT; REVIEW; SEDATION; SELF CONCEPT; SIDE EFFECT; STOMACH PAIN; TACHYCARDIA; TIC; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 1542514004     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849796     Document Type: Review

References (78)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text rev), DSM-IV-TR™. Washington, DC: American Psychiatric Association; 2000:85-93.
2. Leung AK, Robson WL, Fagan JL, et al. Attention-deficit hyperactivity disorder: getting control of impulsive behavior. Postgrad Med. 1994;95:153-160.
3. Guevara JP, Stein MT. Evidence based management of attention hyperactivity disorder. BMJ. 2001;323:1232-1235.
4. Leung AK, Lemay JF. How to treat patients with ADHD. Can J Diagn. 2002;19:97-110.
5. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/ hyperactivity disorder in primary care settings. Pediatrics. 2001;107:e43.
6. Kirby K, Floriani V, Bernstein H. Diagnosis and management of attention-deficit/hyperactivity disorder in children. Curr Opin Pediatr. 2001;13:190-199.
7. Szymanski ML, Zolotor AL. Attention-deficit/hyperactivity disorder: management. Am Fam Physician. 2001;64:1355-1362.
8. Buttross SL. Attention deficit-hyperactivity disorder and its deceivers. Curr Probl Pediatr. 2000;30:37-50.
9. Dunne JE. Attention-deficit/hyperactivity disorder and associated childhood disorders. Prim Care. 1999;26:349-372.
10. DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics. 1998;102:1415-1421.
11. Lou HC. Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatr. 1996;85:1266-1271.
12. Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am. 2001;85:757-777.
13. Taylor MA. Evaluation and management of attention-deficit hyperactivity disorder. Am Fam Physician. 1997;55:887-901.
14. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-1107.
15. Barr CL, Wigg KG, Bloom S, et al. Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am J Med Genet. 2000;96:244-250.
16. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette Syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999;88:358-368.
17. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann Rev Med. 2002;53:113-131.
18. Mercugliano M. What is attention-deficit/hyperactivity disorder? Pediatr Clin North Am. 1999;46:831-843.
19. Simms MD. Attention deficit hyperactivity disorder. In: Behrman RE, Kleigman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. Philadelphia, Pa: W.B. Saunders; 2004:107-110.
20. Filipek PA, Semrud-Clikeman M, Steingard RJ, et al. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology. 1997;48:589-601.
21. Hynd GW, Hern KL, Novey ES, et al. Attention deficit hyperactivity disorder and asymmetry of the caudate nucleus. J Child Neurol. 1993;8:339-347.
22. Mostofsky S, Reiss AL, Lockhart P, et al. Evaluation of cerebellar size in attention-deficit hyperactivity disorder. J Child Neurol. 1998;13:434-439.
23. Zametkin AJ, Liebenaurer LL, Fitzgerald GA, et al. Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1993;50:333-340.
24. Ernst M, Zametkin AJ, Matochik JA, et al. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults: a [fluorine-8] fluorodopa positron emission tomographic study. J Neurosci. 1998;18:5901-5907.
25. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132-2133.
26. McGough JJ, McCracken JT. Assessment of attention deficit hyperactivity disorder: a review of recent literature. Curr Opin Pediatr. 2000;12:319-324.
27. Morgan A, Hynd G, Riccio C, et al. Validity of DSM-IV ADHD predominantly inattentive and combined types: relationship to previous DSM diagnosis/subtype differences. J Am Acad Adolesc Psychiatry. 1996;35:325-333.
28. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin North Am. 2000;9:481-498.
29. Jensen PS, Martin BA, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-IV. J Am Acad Child Adolesc Psychiatry. 1997;36:1065-1079.
30. Owens JA, Maxim R, Nobile C, et al. Parental and self-report of sleep in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2000;154:549-555.
31. Robson WL, Jackson HP, Blackhurst D, Leung AK. Enuresis in children with attention-deficit hyperactivity disorder. South Med J. 1997;90:503-505.
32. Heffron WM, Martin CA, Welsh RJ, et al. Hyperactivity and child abuse. Can J Psychiatry. 1987;32:384-386.
33. Hechtman L, Weiss G. Controlled prospective fifteen year follow-up of hyperactives as adults: non-medical drug and alcohol use and anti-social behavior. Can J Psychiatry. 1986;31:557-567.
34. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98:1089-1095.
35. Levy F, Ward PB. Neurometrics, dynamic brain imaging and attention deficit hyperactivity disorder. J Paediatr Child Health. 1995;31:279-283.
36. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guidelines: treatment of the school-aged child with attention deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
37. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56:1088-1096.
38. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dextroamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662-666.
39. Valentine J, Zubrick S, Sly P. National trends in the use of stimulant medication for attention deficit hyperactivity disorder. J Paediatr Child Health. 1996;32:223-227.
40. Barkley RA, Murphy JV. Treating attention-deficit hyperactivity disorder: medication and behavior management training. Pediatr Ann. 1991;20:256-266.
41. Elia J, Ambrosini PF, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med. 1999;340:780-788.
42. Wolraich ML, Baumgaertel A. The practical aspects of diagnosing and managing children with attention deficit hyperactivity disorder. Clin Pediatr. 1997;36:497-504.
43. Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:e39.
44. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:e105.
45. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42:424-433.
46. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:883-892.
47. Adesman AR. New medications for treatment of children with attention-deficit/hyperactivity disorder: review and commentary. Pediatr Ann. 2002;31:514-522.
48. Auiler JF, Liu K, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFÉ) study. Curr Med Res Opin. 2002;18:311-316.
49. Dirksen SJ, D'Imperio JM, Birdsall D, et al. A postmarketing clinical experience study of Metadate CD. Curr Med Res Opin. 2002;18:371-380.
50. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266.
51. McCough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SL1381 (Adderall XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry. 2003;42:684-691.
52. McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SL1381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673-683.
53. Adesman AR, Morgan AM. Management of stimulant medications in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:945-963.
54. Rasbury WC. Attention deficit disorder: an overview. Henry Ford Hosp Med J. 1988;36:212-216.
55. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grow up: V. Replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77-83.
56. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med. 1999;340:40-46.
57. Tan G, Schneider SC. Attention-deficit hyperactivity disorder: pharmacotherapy and beyond. Postgrad Med. 1997;101:201-222.
58. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo-controlled study of desipramine in the treatment of ADHD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
59. Hunt RD, Paguin A, Payton K. An update on assessment and treatment of complex attention-deficit hyperactivity disorder. Pediatr Ann. 2001;30:162-172.
60. Reitz SJ. Attention-deficit/hyperactivity disorder: focus on pharmacologic management. J Pediatr Health Care. 1997;11:78-83.
61. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:792-797.
62. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQ. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-1036.
63. Szymanski ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. Am Fam Physician. 2001;64:1355-1362.
64. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQ. Pediatrics. 2002;110:e34.
65. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part 1. J Am Acad Child Adolesc Psychiatry. 2000;39:908-919.
66. Canadian Pediatric Society, Mental Health Committee. Use of methylphenidate for attention deficit hyperactivity disorder. Can Med Assoc J. 1990;142:817-818.
67. Safer DJ. Major treatment considerations for attention-deficit hyperactivity disorder. Curr Probl Pediatr. 1995;25:137-143.
68. Leung AK, Robson WL, Lim SH. Counseling parents about childhood discipline. Am Fam Physician. 1992;45:1185-1190.
69. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:977-992.
70. Burgess JR, Stevens L, Zhang W, et al. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr. 2000;71:S327-S330.
71. Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761-768.
72. Boyd WD, Campbell SE. EEG biofeedback in the schools: the use of EEG biofeedback to treat ADHD in a school setting. J Neurother. 1998;2:65-71.
73. Linden M, Gevirtz R, Isenhart R, et al. Event related potentials of subgroups of children with attention deficit hyperactivity disorder and the implications for EEG biofeedback. J Neurother. 1996;1:1-11.
74. Baydala L, Wikman E. The efficacy of neurofeedback in the management of children with attention deficit/hyperactivity disorder. Paediatr Child Health. 2001;6:451-455.
75. Voigt RG, Llorenta AM, Jensen CL, et al. A randomized, double-blind, placebo-controlled trial of docosachexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. 2001;139:189-196.
76. Robin AL. Attention-deficit/hyperactivity disorders in adolescents: common pediatric concerns. Pediatr Clin North Am. 1999;46:1027-1038.
77. Swanson JM, Sergeant JA, Taylor E. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet. 1998;351:429-433.
78. Hechtman L. Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:1039-1052.